Breakthrough Eczema Treatment Won’t Come Cheap
The drug will cost $37,000 a year. The FDA also has approved the first drug to treat severe multiple sclerosis.
The New York Times:
Severe Eczema Drug Is Approved By F.D.A.; Price Tag Is $37,000 A Year
The Food and Drug Administration on Tuesday approved a drug to treat people with a serious form of eczema, a potential breakthrough for people who have suffered for years without relief. But it will not come cheap. The drug, to be called Dupixent, will carry a list price of $37,000 a year, a hefty price tag for patients who are increasingly being asked to pay a larger share of the drugs they take. (Thomas, 3/28)
The New York Times:
F.D.A. Approves First Drug To Treat Severe Multiple Sclerosis
The Food and Drug Administration approved on Tuesday the first drug to treat a severe form of multiple sclerosis, offering hope to patients who previously had no other options to combat a relentless disease that leads to paralysis and cognitive decline. The federal agency also cleared the drug to treat people with the more common, relapsing form of the disease. (Thomas, 3/28)
The Wall Street Journal:
FDA Nominee Plans Recusals From Decisions On Many Drug Firms
The Trump administration’s nominee to lead the Food and Drug Administration plans to recuse himself for a year from FDA decisions on more than 20 companies, including some drug giants. Scott Gottlieb in recent years has held positions and received millions of dollars in income as adviser, executive, paid speaker or consultant to the companies, according to financial-disclosure documents he has filed with government ethics officials. (Burton, 3/29)